RxDoctor Payments Data

Brian Seifman, MD

Urology · West Bloomfield, MINPI 1831171669

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (43.8%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 47 manufacturers reported payments, led by Bayer at 32.6% of the total.

$20,638in general payments, 2019–2025

Across 282 payments — averaging $73.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$7K
  • Johnson & Johnson$4K
  • Avyxa Pharma, LLC$3K
  • Dendreon Pharmaceuticals LLC$1K
  • Ferring Pharmaceuticals Inc.$630
  • Pfizer$404
  • plus $5K from 41 others

What the payments were for

  • Consulting fees$9,03944%
  • Speaking & faculty fees$2,00010%
  • Travel & lodging$2,38312%
  • Food & beverage$7,19435%
  • Education$220%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,638 in reported general payments places this provider in the 85th percentile of 400 urology providers in Michigan.

See all urology providers in Michigan

Medicare billing

Part B allowed, 2024
$686,361
Medicare patients
1,465
Services billed
15,405

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide119$1,579,910
Abiraterone Acetate68$174,554
MyrbetriqMirabegron157$145,231
OrgovyxRelugolix37$94,122
Mirabegron ErMirabegron46$32,230
GemtesaVibegron35$31,764
Tolterodine Tartrate ErTolterodine Tartrate210$23,959
Tamsulosin Hcl1,083$22,772
Trospium Chloride ErTrospium Chloride77$20,499
Alfuzosin Hcl ErAlfuzosin Hcl477$15,646
Dutasteride234$10,260
Testosterone61$7,497
Solifenacin Succinate103$7,154
Potassium Citrate ErPotassium Citrate73$6,728
JatenzoTestosterone Undecanoate12$6,417

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$355$1,725,142276 claims
Janssen Scientific Affairs, LLCAbiraterone Acetate$326$174,55468 claims
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$179$125,88672 claims
Clarus Therapeutics Inc.Jatenzo$67$6,41712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 400 urology providers in Michigan.

Other urology in West Bloomfield

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →